Dalpiciclib with letrozole for metastatic breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, dalpiciclib and letrozole, as maintenance therapy after first-line chemotherapy for HR-positive, HER2-negative metastatic breast cancer. The goal is to see if this combination helps keep the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hormone-receptor positive, HER2-negative breast cancer that has returned or spread.
- You are between 18 and 75 years old.
- You are able to perform daily activities (ECOG performance status 0-1).
- Your liver and kidney function are within normal limits.
- You agree to use contraception during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This study tests a new combination of two medications given before surgery for stage II-III hormone-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes, possibly making surgery more successful.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.